The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...

Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and formulation capabilities with the launch of a GMP-like mRNA manufacturing ...

Broad liver distribution and slightly delayed mRNA expression in human hepatocytes were observed, reinforcing the model’s value in studying human-specific responses to LNP-based therapies.

Figure 3: Options for LNP formulation To complete the process, the bulk LNP encapsulating the mRNA must be sterile-filtered and filled in the final container (e.g., vial, syringe, etc.), labeled ...

In Carisma’s in vivo CAR-M, mRNA is shuttled to macrophages while they’re still in the body to engineer them to go after liver cancer.

YOLT-201 Injection utilizes several lipid components including ionizable lipids as primary excipients to encapsulate mRNA and sgRNA raw materials, forming lipid nanoparticles (LNP).

Here are seven mRNA companies that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials.

The LNP manufacturing process based on Pantherna’s proprietary LNP formulation technology PTXΔLNP© was transferred from Pantherna to Wacker Biotech as part of this project. The resultant mRNA ...